India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.

China's Bio-Thera Solutions has entered into an exclusive commercialization agreement with India's Dr. Reddy's Laboratories ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

The Wright Way Enterprises (TWW), a trusted leader in cybersecurity compliance and program management, has released a new white paper to guide state agencies through the transition to the Centers for ...

MCAP Inc. , a financial technology company, today reported fourth quarter 2024 earnings of $0.15 per share. Annual total revenue was $87.8mm, resulting in EBITDA of $9.2mm and $0.23 per ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, ...

Amidst a backdrop of economic uncertainty and inflation concerns, global markets have experienced a downturn, with U.S. stock indexes falling due to trade policy uncertainties and growth worries. In ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or ...

Amidst a backdrop of economic uncertainty and inflation concerns, global markets have been grappling with trade policy shifts and fluctuating consumer sentiment. As investors navigate these turbulent ...

No matter how high the inflation is, their demand is inelastic. No matter how slow the current profit growth is, these companies spend on research and development (R&D) for future growth.

An estimated 6.5 million people develop invasive fungal infections each year, with about 2.5 million deaths directly caused by them - roughly twice the global toll of tuberculosis.

Learn more about whether Corcept Therapeutics Incorporated or Viatris Inc. is a better investment based on AAII's A+ Investor ...